CAS 1116743-46-4

SAR125844 

CAS: 1116743-46-4

Fórmula: C₂₅H₂₃FN₈O₂S₂

Pureza: %

Forma y color: Solid

Peso molecular: 550.6309

Ref: IN-DA008ZUL

SAR125844

CAS: 1116743-46-4

SAR125844

Pureza: ≥98%

Peso molecular: 550.63g/mol

Ref: 54-BUP08998

1-(6-((6-(4-Fluorophenyl)-[1,2,4]Triazolo[4,3-b]Pyridazin-3-Yl)Thio)Benzo[D]Thiazol-2-Yl)-3-(2-Morpholinoethyl)Urea

CAS: 1116743-46-4

1-(6-((6-(4-Fluorophenyl)-[1,2,4]Triazolo[4,3-b]Pyridazin-3-Yl)Thio)Benzo[D]Thiazol-2-Yl)-3-(2-Morpholinoethyl)Urea

Pureza: 98+%

Peso molecular: 550.63g/mol

Ref: 54-PC108752

SAR125884 hydrochlorid (1116743-46-4(free base))

CAS: 1116743-46-4

SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).

Fórmula: C₂₅H₂₃FN₈O₂S₂·HCl

Pureza: 97.95%

Forma y color: Solid

Peso molecular: 587

Ref: TM-T5677

SAR125844

CAS: 1116743-46-4

SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L)

Fórmula: C₂₅H₂₃FN₈O₂S₂

Pureza: 98.73%

Forma y color: Solid

Peso molecular: 550.63

Ref: TM-T5467

SAR125844

CAS: 1116743-46-4

SAR125844 is a potent inhibitor of the tyrosine kinase activity of epidermal growth factor receptor (EGFR). It has been shown to inhibit tumor growth in animal models and inhibit cell proliferation in cancer cells. SAR125844 has been evaluated in clinical studies for the treatment of patients with prostate cancer, which is resistant to imatinib. The drug was found to be safe and well tolerated at doses up to 800 mg/day. Clinical response rates were observed in some patients who had experienced disease progression while on other therapies. SAR125844 inhibits tumor growth by targeting EGFR, which is an important cellular pathway that promotes cell proliferation and survival.

Fórmula: C₂₅H₂₃FN₈O₂S₂

Pureza: Min. 95%

Peso molecular: 550.63 g/mol

Ref: 3D-RUB74346